Bi-functional cancer treatment agents

Details Bi-functional cancer treatment agents Bi-functional cancer treatment agents

C - Chemistry, Metallurgy

12

N

C12N 15/16 (2006.01) A61K 38/22 (2006.01) C07K 14/55 (2006.01) C07K 14/575 (2006.01) C12N 15/62 (2006.01) A61K 38/00 (2006.01)

Patent

CA 2404088

A novel fusion protein, comprising a receptor-antagonizing domain and a positive immunomodulator domain, characterized, for example, by its ability to block apoptosis and/or inhibit endocrine response, is useful in treating cancer. For example, a human prolactin antagonist-interleukin 2 (hPRLA-IL-2) fusion protein combines apoptosis induction and immuno-therapy to combat cancer in the breast or prostate.

L'invention concerne une nouvelle protéine hybride comprenant un domaine antagonisant un récepteur et un domaine immuno-modulateur positif. Cette protéine est caractérisée en ce que, par exemple, elle est capable de bloquer l'apoptose et/ou d'inhiber une réponse endocrine 2. Cette protéine est utilisée dans le traitement du cancer. Par exemple, une protéine humaine hybride prolactine antagoniste de l'interleukine 2 (hPRLA-IL-2) combine l'induction de l'apopotose avec l'immuno-thérapie en vue de combattre le cancer du sein ou de la prostate.

Affiliated with

Also associated with

Rating

Bi-functional cancer treatment agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bi-functional cancer treatment agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bi-functional cancer treatment agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1835538